menu
    • menu
    [{"orgOrder":0,"company":"HANDOK","sponsor":"Sosei Group Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Clazosentan Sodium","moa":"EDNRA","graph1":"Neurology","graph2":"Approved FDF","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HANDOK \/ HANDOK","highestDevelopmentStatusID":"15","companyTruncated":"HANDOK \/ HANDOK"},{"orgOrder":0,"company":"HANDOK","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Irbesartan","moa":"||Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"HANDOK \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"HANDOK \/ Sanofi"},{"orgOrder":0,"company":"HANDOK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Irbesartan","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"HANDOK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"HANDOK \/ Inapplicable"},{"orgOrder":0,"company":"HANDOK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Irbesartan","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"HANDOK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"HANDOK \/ Inapplicable"},{"orgOrder":0,"company":"HANDOK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Teneligliptin Hydrobromide","moa":"DPP-4","graph1":"Endocrinology","graph2":"Phase III","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"HANDOK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"HANDOK \/ Inapplicable"},{"orgOrder":0,"company":"HANDOK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Teneligliptin Hydrobromide","moa":"DPP-4","graph1":"Endocrinology","graph2":"Phase III","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"HANDOK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"HANDOK \/ Inapplicable"},{"orgOrder":0,"company":"HANDOK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Irbesartan","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"HANDOK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"HANDOK \/ Inapplicable"},{"orgOrder":0,"company":"HANDOK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Teneligliptin Hydrobromide","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"HANDOK \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"HANDOK \/ Inapplicable"},{"orgOrder":0,"company":"HANDOK","sponsor":"AUM Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AUM601","moa":"TRKA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"HANDOK \/ HANDOK","highestDevelopmentStatusID":"6","companyTruncated":"HANDOK \/ HANDOK"},{"orgOrder":0,"company":"HANDOK","sponsor":"AUM Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"CHC2014","moa":"Pan-TRK","graph1":"Oncology","graph2":"Phase I","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"HANDOK \/ AUM Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"HANDOK \/ AUM Biosciences"},{"orgOrder":0,"company":"HANDOK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HD-P023","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"HANDOK \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HANDOK \/ Inapplicable"},{"orgOrder":0,"company":"HANDOK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HD-P023","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"HANDOK \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HANDOK \/ Inapplicable"},{"orgOrder":0,"company":"HANDOK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ketoprofen","moa":"Cyclooxygenase","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical","sponsorNew":"HANDOK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"HANDOK \/ Inapplicable"},{"orgOrder":0,"company":"HANDOK","sponsor":"Compass Therapeutics | ABL Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CTX-009","moa":"DLL4\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HANDOK \/ Compass Therapeutics | ABL Bio","highestDevelopmentStatusID":"7","companyTruncated":"HANDOK \/ Compass Therapeutics | ABL Bio"},{"orgOrder":0,"company":"HANDOK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Irbesartan","moa":"Type-1 angiotensin II receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HANDOK \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HANDOK \/ Inapplicable"},{"orgOrder":0,"company":"HANDOK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Irbesartan","moa":"Type-1 angiotensin II receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HANDOK \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HANDOK \/ Inapplicable"},{"orgOrder":0,"company":"HANDOK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Irbesartan","moa":"Type-1 angiotensin II receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HANDOK \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HANDOK \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by HANDOK

    Menu

    HANDOK

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            HANDOK

                            South Korea arrow
                            ChemOutsourcing
                            Not Confirmed

                            HANDOK

                            South Korea arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HD-P023

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Health...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 21, 2025

                            Lead Product(s) : HD-P023

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            HANDOK

                            South Korea arrow
                            ChemOutsourcing
                            Not Confirmed

                            HANDOK

                            South Korea arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clazosentan Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : Sosei Group Corporation

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Nxera Pharma Announces Exclusive Supply Agreement with Handok for Pivlaz™

                            Details : Handok is responsible for commercialization of Pivlaz (clazosentan sodium), approved in South Korea for preventing cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage.

                            Product Name : Pivlaz

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 14, 2024

                            Lead Product(s) : Clazosentan Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : Sosei Group Corporation

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            HANDOK

                            South Korea arrow
                            ChemOutsourcing
                            Not Confirmed

                            HANDOK

                            South Korea arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HD-P023

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteer...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 01, 2024

                            Lead Product(s) : HD-P023

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            HANDOK

                            South Korea arrow
                            ChemOutsourcing
                            Not Confirmed

                            HANDOK

                            South Korea arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Irbesartan,Amlodipine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Sanofi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Handok and Sanofi Launch “Aprovasc,” a Combination Antihypertensive Drug, in South Korea

                            Details : Aprovasc (Irbesartan + amlodipine) is an angiotensin II receptor blocker, small molecule drug candidate, which is indicated for the treatment of hypertension and diabetic nephropathy.

                            Product Name : Aprovasc

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 01, 2024

                            Lead Product(s) : Irbesartan,Amlodipine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Sanofi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            HANDOK

                            South Korea arrow
                            ChemOutsourcing
                            Not Confirmed

                            HANDOK

                            South Korea arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Irbesartan

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics of Irbesartan High/Amlodipine FDC and Co-administration of Irbesartan High and Amlodipine in ...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 18, 2023

                            Lead Product(s) : Irbesartan

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            HANDOK

                            South Korea arrow
                            ChemOutsourcing
                            Not Confirmed

                            HANDOK

                            South Korea arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Irbesartan

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics of Irbesartan/Amlodipine High FDC and Co-administration of Irbesartan and Amlodipine High in ...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 18, 2023

                            Lead Product(s) : Irbesartan

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            HANDOK

                            South Korea arrow
                            ChemOutsourcing
                            Not Confirmed

                            HANDOK

                            South Korea arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Irbesartan

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics of Irbesartan/Amlodipine FDC and Co-administration of Irbesartan and Amlodipine in Healthy Vo...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 23, 2022

                            Lead Product(s) : Irbesartan

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            HANDOK

                            South Korea arrow
                            ChemOutsourcing
                            Not Confirmed

                            HANDOK

                            South Korea arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Teneligliptin Hydrobromide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Contr...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 17, 2022

                            Lead Product(s) : Teneligliptin Hydrobromide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            HANDOK

                            South Korea arrow
                            ChemOutsourcing
                            Not Confirmed

                            HANDOK

                            South Korea arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Teneligliptin Hydrobromide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Contr...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 17, 2022

                            Lead Product(s) : Teneligliptin Hydrobromide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            HANDOK

                            South Korea arrow
                            ChemOutsourcing
                            Not Confirmed

                            HANDOK

                            South Korea arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Irbesartan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypert...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 27, 2022

                            Lead Product(s) : Irbesartan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth